Cepheid 2013 sales of CT/NG estimated $15M-$20M at William Blair William Blair expects solid initial demand for Cepheid's just approved Xpert CT/NG from existing Xpert customers and projects 2013 sales between $15M-$20M on a worldwide basis. However, William Blair says it is not sure if Cepheid will be able to ship enough product to meet initial demand as it provided no update on the recent manufacturing issues. The firm keeps an Outperform rating on the stock.
Cepheid upgraded to Buy from Hold at Craig-Hallum Craig-Hallum upgraded Cepheid to Buy and raised its price target to $75 from $52. The firm said Cepheid is rapidly expanding its clinical offering and customer reach and is emerging as the leading platform for molecular diagnostics.